CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival

Journal of Clinical Pathology

Volumn 68, Issue 3, 2015, Pages 200-205

  Chong, Tsung Wen ^a   Goh, Fera Yiqian ^a   Sim, Mei Yi ^a   Huang, Hong Hong ^a   Thike, Daw Aye Aye ^a   Lim, Weng Khong ^b,c   Teh, Bin Tean ^b,c,d   Tan, Puay Hoon ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD1D PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HOST; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TISSUE MICROARRAY; CARCINOMA, RENAL CELL; CHI SQUARE DISTRIBUTION; DISEASE COURSE; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; UPREGULATION;

AGED; ANTIGENS, CD1D; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84923588608     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202735     Document Type: Article

References (27)

1. Snow RM, Schellhammer PF. Spontaneous regression of metastatic renal cell carcinoma. Urology 1982;20:177-81.
2. Rosenberg SA. Interleukin 2 for patients with renal cancer. Nat Clin Pract Oncol 2007;4:497.
3. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-5.
4. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 2012;366:2455-65.
5. Krambeck AE, Thompson RH, Dong H, et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 2006;103:10391-6.
6. Crispen PL, Sheinin Y, Roth TJ, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008;14:5150-7.
7. Saito T, Yamagata T, Takahashi T, et al. ICSAT overexpression is not sufficient to cause adult T-cell leukemia or multiple myeloma. Biochem Biophys Res Commun 1999;260:329-31.
8. Das T, Sa G, Hilston C, et al. GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis. Cancer Res 2008;68:2014-23.
9. Biswas S, Biswas K, Richmond A, et al. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol 2009;183:5050-8.
10. Sa G, Das T, Moon C, et al. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 2009;69:3095-104.
11. Kawasaki Y, Ito A, Withers DA, et al. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells. Glycobiology 2010;20:1373-9.
12. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997;278:1626-9.
13. Fais F, Tenca C, Cimino G, et al. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia 2005;19:551-6.
14. Metelitsa LS, Weinberg KI, Emanuel PD, et al. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003;17:1068-77.
15. Xu C, de Vries R, Visser L, et al. Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. Am J Hematol 2010;85:539-41.
16. Fais F, Morabito F, Stelitano C, et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer 2004;109:402-11.
17. Webb TJ, Li X, Giuntoli RL II, et al. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res 2012;72:3744-52.
18. Canchis PW, Bhan AK, Landau SB, et al. Tissue distribution of the non-polymorphic major histocompatibility complex class I-like molecule, CD1d. Immunology 1993;80:561-5.
19. Dhodapkar KM, Cirignano B, Chamian F, et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer 2004;109:893-9.
20. Terabe M, Berzofsky JA. The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. Cancer Immunol Immunother 2014;63:199-213.
21. Mussai F, De Santo C, Cerundolo V. Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities. J Immunother 2012;35:449-59.
22. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 2006;50:34-43.
23. Polimeno M, Napolitano M, Costantini S, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int 2013;112:686-96.
24. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-53.
25. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075-81.
26. Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721s-26s.
27. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.